Schaaf H S, Wademan D T, van der Laan L E
Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
IJTLD Open. 2025 Sep 10;2(9):501-504. doi: 10.5588/ijtldopen.25.0446. eCollection 2025 Sep.
An increasing number of children are diagnosed and started on antituberculosis treatment. Despite progress in developing child-friendly antituberculosis formulations for drug-susceptible and drug-resistant TB, a single-medicine rifampicin dispersible tablet is still needed. Further, many child-friendly dispersible solid-tablet formulations are not available globally. Access challenges lead to formulation manipulation of adult tablets, including the development of extemporaneous solutions, supported by pharmacokinetic studies to dose young children. Preparing extemporaneous formulations need pharmacies and trained staff. Therefore, a need remains for global collaboration to prioritise child-friendly solid, dispersible, functionally scored TB formulations and to ensure equal access for all children with TB globally.
越来越多的儿童被诊断出患有结核病并开始接受抗结核治疗。尽管在开发适用于药物敏感和耐药结核病的儿童友好型抗结核制剂方面取得了进展，但仍需要一种单药利福平分散片。此外，许多儿童友好型分散片剂在全球范围内都无法获得。获取方面的挑战导致对成人片剂进行剂型调整，包括开发临时溶液，并通过药代动力学研究来确定幼儿的剂量。制备临时制剂需要药房和经过培训的工作人员。因此，仍然需要全球合作，优先开发儿童友好型固体、可分散、功能可评分的结核病制剂，并确保全球所有结核病儿童都能平等获得这些制剂。
